arrow
L

Loredana Puca

Weill Cornell Medicine
H指数:23
被引数:5,783

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
2024-08-082
OAAI
Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer
2024-07-185
OAAI
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
2023-04-040
PRE
LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models

LOXO-783: 一种有效的,高度突变的选择性和脑渗透变构PI3Kα H1047R抑制剂与临床前PI3Kα H1047R-mutant乳腺癌模型的护理标准 (SOC) 联合治疗

2023-03-013
PRE
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
Science
IF45.8
2022-01-010
OA
Preclinical characterization of LOX-22783, a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor
2021-12-019
PRE
Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors
2021-11-1435
OA
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer
2021-11-0419
OAAI
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity
2020-11-0377
OAAI
N-Myc mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer
2019-08-19137
OA
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

Delta样蛋白3在神经内分泌前列腺癌中的表达及靶向治疗

2019-03-20139
OAAI
ONECUT2 is a driver of neuroendocrine prostate cancer

ONECUT2是神经内分泌前列腺癌的驱动因素

2019-01-17196
OAAI
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers

Aurora激酶A抑制剂Alisertib治疗去势抵抗性和神经内分泌前列腺癌患者的II期临床试验: 疗效和生物标志物

2019-01-03252
OAAI